Revision of Applications for Manufacturing and Procurement Quotas
DEA proposes to revise regulations for manufacturing and procurement quotas for schedule I/II controlled substances and list I chemicals, affecting how quotas are applied for and managed.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Pharmacies and entities that manufacture or procure schedule I/II controlled substances or list I chemicals (ephedrine, pseudoephedrine). should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comments due by July 20, 2026; final rule effective date TBD.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The DEA is revising the application process for manufacturing and procurement quotas, likely including new requirements, timelines, or documentation.
Who it affects
Pharmacies and entities that manufacture or procure schedule I/II controlled substances or list I chemicals (ephedrine, pseudoephedrine).
What you must do
Review the proposed rule and prepare to adjust quota application procedures to comply with new requirements once finalized.
Deadline
Comments due by July 20, 2026; final rule effective date TBD.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
- Amanda Ward, N.D.; Decision and Order